Structure-guided residence time optimization of a dabigatran reversal agent

References

• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442; PMID:17132052; http://dx.doi.org/10.1371/journal.pmed.0030442
   PubMed Web of Science ®Google Scholar
• Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119:8S-21S; PMID:11157640; http://dx.doi.org/10.1378/chest.119.1_suppl.8S
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:204S-33S; PMID:15383473; http://dx.doi.org/10.1378/chest.126.3_suppl.204S
   PubMed Web of Science ®Google Scholar
• Jones M, McEwan P, Morgan CL, Peters J, Goodfellow J, Currie C. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91:472-7; PMID:15772203; http://dx.doi.org/10.1136/hrt.2004.042465
   PubMed Web of Science ®Google Scholar
• Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005; 21:1583-94; PMID:16238898; http://dx.doi.org/10.1185/030079905X61956
   PubMed Web of Science ®Google Scholar
• Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005; 46:1729-36; PMID:16256877; http://dx.doi.org/10.1016/j.jacc.2005.06.077
   PubMed Web of Science ®Google Scholar
• Hauel NH, Nar H, Priepke H, Ries U, Stassen J-M, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45:1757-66; PMID:11960487; http://dx.doi.org/10.1021/jm0109513
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Disposition 2008; 36:386-99; http://dx.doi.org/10.1124/dmd.107.019083
   PubMed Web of Science ®Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47:285-95; PMID:18399711; http://dx.doi.org/10.2165/00003088-200847050-00001
   PubMed Web of Science ®Google Scholar
• Majeed A, Hwang H-G, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128:2325-32; PMID:24081972; http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002332
   PubMed Web of Science ®Google Scholar
• Schiele F, van Ryn J, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121:3554-62; PMID:23476049; http://dx.doi.org/10.1182/blood-2012-11-468207
   PubMed Web of Science ®Google Scholar
• Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, Lang B, Ramael S, Reilly P. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113:943-51; PMID:25789661; http://dx.doi.org/10.1160/TH14-12-1080
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113:931-42; PMID:25832311; http://dx.doi.org/10.1160/TH14-11-0982
   PubMed Web of Science ®Google Scholar
• Bork P, Holm L, Sander C. The immunoglobulin fold: structural classification, sequence patterns and common core. J Mol Biol 1994; 242:309-20; PMID:7932691
   PubMed Web of Science ®Google Scholar
• Burley S, Petsko G. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science 1985; 229:23-8; PMID:3892686; http://dx.doi.org/10.1126/science.3892686
   PubMed Web of Science ®Google Scholar
• Meyer EA, Castellano RK, Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed 2003; 42:1210-50; http://dx.doi.org/10.1002/anie.200390319
   PubMed Web of Science ®Google Scholar
• Gallivan JP, Dougherty DA. Cation-π interactions in structural biology. Proc Natl Acad Sci U S A 1999; 96:9459-64; PMID:10449714; http://dx.doi.org/10.1073/pnas.96.17.9459
   PubMed Web of Science ®Google Scholar
• Richter F, Leaver-Fay A, Khare SD, Bjelic S, Baker D. De novo enzyme design using Rosetta3. PLoS One 2011; 6:e19230; PMID:21603656; http://dx.doi.org/10.1371/journal.pone.0019230
   PubMed Web of Science ®Google Scholar
• Copeland RA, Pompliano DL, Meek TD. Drug–target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006; 5:730-9; PMID:16888652; http://dx.doi.org/10.1038/nrd2082
   PubMed Web of Science ®Google Scholar
• Swinney DC. Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 2006; 6:461-78; PMID:16719803; http://dx.doi.org/10.2174/156802606776743093
   PubMed Web of Science ®Google Scholar
• Niemi MH, Turunen L, Pulli T, Nevanen TK, Höyhtyä M, Söderlund H, Rouvinen J, Takkinen K. A Structural Insight into the Molecular Recognition of a (−)-Δ< sup> 9-Tetrahydrocannabinol and the Development of a Sensitive, One-Step, Homogeneous Immunocomplex-Based Assay for Its Detection. J Mol Biol 2010; 400:803-14; PMID:20630472; http://dx.doi.org/10.1016/j.jmb.2010.05.048
   PubMed Web of Science ®Google Scholar
• Leysath CE, Monzingo AF, Maynard JA, Barnett J, Georgiou G, Iverson BL, Robertus JD. Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen. J Mol Biol 2009; 387:680-93; PMID:19361425; http://dx.doi.org/10.1016/j.jmb.2009.02.003
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Fieser TM, Lerner RA, Wilson IA. Crystal structures of an antibody to a peptide and its complex with peptide antigen at 2.8 A. Science 1990; 248:712-9; PMID:2333521; http://dx.doi.org/10.1126/science.2333521
   PubMed Web of Science ®Google Scholar
• Pozharski E, Wilson MA, Hewagama A, Shanafelt AB, Petsko G, Ringe D. Anchoring a cationic ligand: the structure of the Fab fragment of the anti-morphine antibody 9B1 and its complex with morphine. J Mol Biol 2004; 337:691-7; PMID:15019787; http://dx.doi.org/10.1016/j.jmb.2003.12.084
   PubMed Web of Science ®Google Scholar
• James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science 2003; 299:1362-7; PMID:12610298; http://dx.doi.org/10.1126/science.1079731
   PubMed Web of Science ®Google Scholar
• Rini JM, Schulze-Gahmen U, Wilson IA. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science 1992; 255:959-65; PMID:1546293; http://dx.doi.org/10.1126/science.1546293
   PubMed Web of Science ®Google Scholar
• Koshland D Jr. Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci U S A 1958; 44:98; PMID:16590179; http://dx.doi.org/10.1073/pnas.44.2.98
   PubMed Web of Science ®Google Scholar
• Kumar S, Ma B, Tsai CJ, Sinha N, Nussinov R. Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci 2000; 9:10-9; PMID:10739242; http://dx.doi.org/10.1110/ps.9.1.10
   PubMed Web of Science ®Google Scholar
• Estabrook RA, Reich N. Observing an induced-fit mechanism during sequence-specific DNA methylation. J Biol Chem 2006; 281:37205-14; PMID:17005571; http://dx.doi.org/10.1074/jbc.M607538200
   PubMed Web of Science ®Google Scholar
• Wilson IA, Stanfield RL. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol 1994; 4:857-67; PMID:7536111; http://dx.doi.org/10.1016/0959-440X(94)90267-4
   PubMed Web of Science ®Google Scholar
• Okazaki KI, Takada S. Dynamic energy landscape view of coupled binding and protein conformational change: induced-fit vs. population-shift mechanisms. Proc Natl Acad Sci U S A 2008; 105:11182-7; PMID:18678900; http://dx.doi.org/10.1073/pnas.0802524105
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117:63S-6S; PMID:10673478; http://dx.doi.org/10.1378/chest.117.2_suppl.63S
   PubMed Web of Science ®Google Scholar
• Luckner SR, Liu N, am Ende CW, Tonge PJ, Kisker C. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J Biol Chem 2010; 285:14330-7; PMID:20200152; http://dx.doi.org/10.1074/jbc.M109.090373
   PubMed Web of Science ®Google Scholar
• Schneider EV, Böttcher J, Huber R, Maskos K, Neumann L. Structure–kinetic relationship study of CDK8/CycC specific compounds. Proc Natl Acad Sci USA 2013; 110:8081-6; PMID:23630251; http://dx.doi.org/10.1073/pnas.1305378110
   PubMed Web of Science ®Google Scholar
• Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, Womack T, Bricogne G. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr Sect D Biol Crystallogr 2011; 67:293-302; PMID:21460447; http://dx.doi.org/10.1107/S0907444911007773
   PubMed Web of Science ®Google Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007; 40:658-74; PMID:19461840; http://dx.doi.org/10.1107/S0021889807021206
   PubMed Web of Science ®Google Scholar
• Potterton E, Briggs P, Turkenburg M, Dodson E. A graphical user interface to the CCP4 program suite. Acta Crystallogr Sect D Biol Crystallogr 2003; 59:1131-7; http://dx.doi.org/10.1107/S0907444903008126
   PubMed Web of Science ®Google Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr Sect D Biol Crystallogr 2011; 67:235-42; PMID:21460441; http://dx.doi.org/10.1107/S0907444910045749
   PubMed Web of Science ®Google Scholar
• Stein N. CHAINSAW: a program for mutating pdb files used as templates in molecular replacement. J Appl Crystallogr 2008; 41:641-3; http://dx.doi.org/10.1107/S0021889808006985
   Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr Sect D Biol Crystallogr 2004; 60:2126-32; http://dx.doi.org/10.1107/S0907444904019158
   PubMed Web of Science ®Google Scholar
• Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, Paciorek W, Roversi P, Sharff A, Smart OS, Vonrhein C, et al. BUSTER. Cambridge, UK: Global Phasing Ltd.; 2011
   Google Scholar
• Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr Sect D Biol Crystallogr 2009; 66:12-21; PMID:20057044; http://dx.doi.org/10.1107/S0907444909042073
   PubMed Web of Science ®Google Scholar
• Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007; 372:774-97; PMID:17681537; http://dx.doi.org/10.1016/j.jmb.2007.05.022
   PubMed Web of Science ®Google Scholar
• Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr Sect D Biol Crystallogr 2004; 60:2256-68; http://dx.doi.org/10.1107/S0907444904026460
   PubMed Web of Science ®Google Scholar